NCT01575548 2026-03-18
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
National Cancer Institute (NCI)
Phase 3 Active not recruiting
Clinical Trials
16 trialsNCT03793166 2026-03-18
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT03055013 2026-03-17
Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT05738694 2026-03-17
Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma
Sun Yat-sen University
Phase 3 Recruiting
NCT07227402 2026-03-16
LITESPARK-033
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT03142334 2026-03-10
KEYNOTE-564
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT06661720 2026-03-04
STRIKE
Alliance for Clinical Trials in Oncology
Phase 3 Recruiting
NCT05863351 2026-03-02
Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study
Eastern Cooperative Oncology Group
Phase 3 Active not recruiting
NCT06959433 2026-02-27
Lu-177 PSMA Treatment in Cell Renal Carcinoma
Ankara University
Phase 3 Not yet recruiting
NCT02811861 2026-02-23
CLEAR
Eisai Inc.
Phase 3 Active not recruiting
NCT07405164 2026-02-12
MK-6482-043
Merck Sharp & Dohme LLC
Phase 3 Not yet recruiting
NCT02853331 2026-02-02
KEYNOTE-426
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03091192 2026-01-23
Savolitinib vs. Sunitinib in MET-driven PRCC.
AstraZeneca
Phase 3 Active not recruiting
NCT07092566 2026-01-20
R.E.C.K vs Exparel in Robotic Nephrectomy
Wake Forest University Health Sciences
Phase 3 Recruiting
NCT06726421 2026-01-15
STROKER
Sun Yat-sen University
Phase 3 Recruiting
NCT06500455 2026-01-14
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
NRG Oncology
Phase 3 Recruiting